NUAK2

Summary

NUAK2 (NUAK family kinase 2, HGNC:29558) is a protein-coding gene on chromosome 1q32.1, encoding NUAK family SNF1-like kinase 2 (Q9H093). Stress-activated kinase involved in tolerance to glucose starvation.

Enables ATP binding activity; magnesium ion binding activity; and protein serine/threonine kinase activity. Involved in several processes, including cellular response to glucose starvation; protein phosphorylation; and regulation of hippo signaling. Located in nuclear speck. Implicated in anencephaly.

Source: NCBI Gene 81788 — RefSeq curated summary.

At a glance

• Gene–disease (curated): anencephaly 2 (Moderate, GenCC)
• GWAS associations: 10
• Clinical variants (ClinVar): 115 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 9
• Druggable target: yes — 34 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_030952

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29558
Approved symbol	NUAK2
Name	NUAK family kinase 2
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	SNARK, FLJ90349
Ensembl gene	ENSG00000163545
Ensembl biotype	protein_coding
OMIM	608131
Entrez	81788

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000367157

RefSeq mRNA: 1 — MANE Select: NM_030952 NM_030952

CCDS: CCDS1453

Canonical transcript exons

ENST00000367157 — 7 exons

Exon	Start	End
ENSE00001075851	205311705	205311825
ENSE00001075853	205308165	205308230
ENSE00001075855	205305199	205305331
ENSE00001075858	205308581	205308732
ENSE00001075861	205306188	205306307
ENSE00001443657	205321398	205321745
ENSE00001607276	205302063	205304513

Expression profiles

Bgee: expression breadth ubiquitous, 220 present calls, max score 95.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.1400 / max 452.8664, expressed in 1521 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16970	18.0189	1519
16968	0.1210	59

Top tissues by expression

274 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cervix squamous epithelium	UBERON:0006922	95.26	gold quality
lower esophagus mucosa	UBERON:0035834	94.78	gold quality
blood	UBERON:0000178	92.37	gold quality
ileal mucosa	UBERON:0000331	92.09	gold quality
oviduct epithelium	UBERON:0004804	91.72	gold quality
tongue squamous epithelium	UBERON:0006919	91.43	gold quality
metanephros cortex	UBERON:0010533	91.26	gold quality
gingival epithelium	UBERON:0001949	90.81	gold quality
cervix epithelium	UBERON:0004801	90.33	gold quality
gingiva	UBERON:0001828	90.19	gold quality
squamous epithelium	UBERON:0006914	89.87	gold quality
esophagus mucosa	UBERON:0002469	89.60	gold quality
pharyngeal mucosa	UBERON:0000355	89.00	gold quality
granulocyte	CL:0000094	88.80	gold quality
epithelium of esophagus	UBERON:0001976	87.89	gold quality
palpebral conjunctiva	UBERON:0001812	87.65	gold quality
esophagus squamous epithelium	UBERON:0006920	87.53	gold quality
renal medulla	UBERON:0000362	86.43	gold quality
mucosa of transverse colon	UBERON:0004991	86.11	gold quality
nephron tubule	UBERON:0001231	86.00	gold quality
kidney epithelium	UBERON:0004819	85.83	gold quality
metanephric glomerulus	UBERON:0004736	85.61	gold quality
jejunal mucosa	UBERON:0000399	85.25	gold quality
upper leg skin	UBERON:0004262	84.68	gold quality
renal glomerulus	UBERON:0000074	84.67	gold quality
oral cavity	UBERON:0000167	84.17	gold quality
vagina	UBERON:0000996	83.98	gold quality
adult mammalian kidney	UBERON:0000082	83.74	gold quality
cortex of kidney	UBERON:0001225	83.73	gold quality
buccal mucosa cell	CL:0002336	83.55	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.02

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

100 targeting NUAK2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-6780A-5P	99.88	66.69	2776

Literature-anchored findings (GeneRIF, showing 23)

• This study describes the cloning and characterization of the rat SNARK homolog, mapping of the human SNARK gene to 1q32, and a potential functional role as mediator of the cellular response to metabolic stress. (PMID:11284715)
• SNARK is an NF-kappaB-regulated anti-apoptotic gene that contributes to the tumor-promoting activity of CD95 in apoptosis-resistant tumor cells (PMID:15345718)
• These data suggests different phosphorylation and regulation of MYPT1 activity by NUAK2. (PMID:18023418)
• EBV LMP1 upregulated the expression of SNARK; SNARK expression increased drug resistance in response to doxorubicin increased of cancer cell survival (PMID:18452098)
• The nuclear localizing SNARK altered transcriptome profiles and a considerable part of these alterations were canceled by the mutation of NLS, suggesting the ability of SNARK to modulate gene expression dependent on its nuclear localization. (PMID:18992219)
• Skeletal muscle SNARK expression is increased in human obesity, and in response to metabolic stressors, but not type 2 diabetes. Partial SNARK depletion failed to modify either glucose or lipid metabolism. (PMID:19652946)
• Data show that SNARK is activated by muscle contraction and is a unique mediator of contraction-stimulated glucose transport in skeletal muscle. (PMID:20713714)
• MLCP (myosin light chain phosphatase) activation is counteracted by a previously unrecognized association between MRIP (myosin phosphatase Rho-interacting protein) and the inducible kinase NUAK2 (PMID:21242312)
• This study further supports the importance of NUAK2 in cancer development and tumor progression, while AMPK has antioncogenic properties. (PMID:21460252)
• Considers possible roles of NUAK2 in tumorigenesis in general and suggest that NUAK2 has pivotal roles in acral melanomagenesis. (PMID:21911917)
• Activation of AMP-activated protein kinase protects the integrity of the blood-brain barrier by suppressing the induction of NADPH oxidase-derived superoxide anions. (PMID:22796592)
• The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-beta signaling. (PMID:23831117)
• Sucrose non-fermenting AMPK related kinase/Pentraxin 3 combined role in immunometabolic signaling and DNA damage response is proposed to accelerate cardiovascular complications in systemic lupus erythematosus patients (PMID:25732129)
• NUAK2 silencing and inactivation of the PI3K pathway efficiently controlled CDK2 expression, whereas CDK2 inactivation specifically abrogated the growth of NUAK2-amplified and PTEN-deficient melanoma cells. (PMID:25832654)
• miR143 inhibited the proliferation, migration and invasion of the glioblastoma cells by degrading NUAK2 in glioblastoma. (PMID:27081712)
• Data (including data from studies in knockout and transgenic mice) suggest that NUAK2/SNARK is involved in both adipose inflammation and energy metabolism in adipocytes; additionally, genome-wide association studies suggest that 2 SNPs in NUAK2/SNARK (rs4682880, rs4682676) are associated with obesity in women. (PMID:29298809)
• NUAK2 localization in normal skin and its expression in a variety of skin tumors with YAP. (PMID:32001115)
• A loss-of-function NUAK2 mutation in humans causes anencephaly due to impaired Hippo-YAP signaling. (PMID:32845958)
• NUAK2 silencing inhibits the proliferation, migration and epithelialtomesenchymal transition of cervical cancer cells via upregulating CYFIP2. (PMID:34558636)
• GPR65 promotes intestinal mucosal Th1 and Th17 cell differentiation and gut inflammation through downregulating NUAK2. (PMID:35343079)
• Circ_0000033 up-regulates NUAK2 by sequestering miR-378a-3p to promote breast tumorigenesis. (PMID:37357410)
• Enhanced SARS-CoV-2 entry via UPR-dependent AMPK-related kinase NUAK2. (PMID:37421942)
• OTUD7B deubiquitinates and stabilizes YAP1 to upregulate NUAK2 expression, thus accelerating gastric cancer procession. (PMID:37429790)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	nuak2	ENSDARG00000063661
mus_musculus	Nuak2	ENSMUSG00000009772
rattus_norvegicus	Nuak2	ENSRNOG00000000034
drosophila_melanogaster	Snrk	FBGN0033915
drosophila_melanogaster	Nuak	FBGN0262617
caenorhabditis_elegans		WBGENE00012638
caenorhabditis_elegans	ZK524.4	WBGENE00013994
caenorhabditis_elegans	tag-344	WBGENE00015230
caenorhabditis_elegans		WBGENE00044388

Paralogs (17): NUAK1 (ENSG00000074590), PRKAA1 (ENSG00000132356), TSSK4 (ENSG00000139908), HUNK (ENSG00000142149), SIK1 (ENSG00000142178), BRSK1 (ENSG00000160469), SIK3 (ENSG00000160584), PRKAA2 (ENSG00000162409), TSSK3 (ENSG00000162526), SNRK (ENSG00000163788), MELK (ENSG00000165304), SIK2 (ENSG00000170145), BRSK2 (ENSG00000174672), NIM1K (ENSG00000177453), TSSK6 (ENSG00000178093), TSSK2 (ENSG00000206203), TSSK1B (ENSG00000212122)

Protein

Protein identifiers

NUAK family SNF1-like kinase 2 — Q9H093 (reviewed: Q9H093)

Alternative names: Omphalocele kinase 2, SNF1/AMP kinase-related kinase

All UniProt accessions (1): Q9H093

UniProt curated annotations — full annotation on UniProt →

Function. Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells. Phosphorylates LATS1 and LATS2. Plays a key role in neural tube closure during embryonic development through LATS2 phosphorylation and regulation of the nuclear localization of YAP1 a critical downstream regulatory target in the Hippo signaling pathway.

Post-translational modifications. Phosphorylated at Thr-208 by STK11/LKB1 in complex with STE20-related adapter-alpha (STRADA) pseudo kinase and CAB39. Autophosphorylation is also possible at Thr-208.

Disease relevance. Anencephaly 2 (ANPH2) [MIM:619452] A form of anencephaly, an extreme neural tube defect resulting in the absence of brain tissues, and death in utero or perinatally. Infants are born with intact spinal cords, cerebellums, and brainstems, but lack formation of neural structures above this level. The skull is only partially formed. ANPH2 features may also include frontonasal dysplasia with midline cleft of the upper lip and alveolar ridge, bifid nose, and clinical anophthalmia. ANPH2 inheritance is autosomal recessive. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Activated by phosphorylation on Thr-208.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. SNF1 subfamily.

RefSeq proteins (1): NP_112214* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (23 total): modified residue 7, sequence variant 6, region of interest 2, mutagenesis site 2, binding site 2, chain 1, domain 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H093-F1	63.45	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 175 (proton acceptor)

Ligand- & substrate-binding residues (2): 59–67; 81

Post-translational modifications (7): 435, 523, 544, 547, 573, 1, 208

Mutagenesis-validated functional residues (2):

Position	Phenotype
81	loss of autophosphorylation, kinase activity and of anti-apoptotic activity.
208	prevents phosphorylation and activation by stk11/lkb1 complex.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 154 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, LEE_NEURAL_CREST_STEM_CELL_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_HIPPO_SIGNALING, RICKMAN_METASTASIS_DN, WTGAAAT_UNKNOWN, AACTTT_UNKNOWN, GOBP_CELLULAR_RESPONSE_TO_STARVATION, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE, TAATGTG_MIR323, GOBP_CELLULAR_RESPONSE_TO_GLUCOSE_STARVATION, GOBP_PROTEIN_LOCALIZATION_TO_NUCLEUS, GOBP_RESPONSE_TO_STARVATION, TGGAAA_NFAT_Q4_01, GOMF_MAGNESIUM_ION_BINDING

GO Biological Process (7): protein phosphorylation (GO:0006468), apoptotic process (GO:0006915), actin cytoskeleton organization (GO:0030036), protein localization to nucleus (GO:0034504), regulation of hippo signaling (GO:0035330), cellular response to glucose starvation (GO:0042149), negative regulation of apoptotic process (GO:0043066)

GO Molecular Function (10): magnesium ion binding (GO:0000287), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
phosphorylation	1
protein modification process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cytoskeleton organization	1
actin filament-based process	1
protein localization to organelle	1
hippo signaling	1
regulation of intracellular signal transduction	1
cellular response to starvation	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
metal ion binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cation binding	1

Protein interactions and networks

STRING

766 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NUAK2	SIK3	Q9Y2K2	603
NUAK2	SIK2	Q9H0K1	540
NUAK2	ARHGEF17	Q96PE2	530
NUAK2	MPRIP	Q6WCQ1	498
NUAK2	SIK1	P57059	474
NUAK2	A0A0B4J2F2	A0A0B4J2F2	472
NUAK2	PTPN14	Q15678	458
NUAK2	ACVR1	Q04771	430
NUAK2	AMOTL2	Q9Y2J4	427
NUAK2	CAB39	Q9Y376	415
NUAK2	WDR49	Q8IV35	408
NUAK2	PPP1R12A	O14974	407
NUAK2	PLEKHH3	Q7Z736	399
NUAK2	XRN1	Q8IZH2	389
NUAK2	PLA2G4C	Q9UP65	387

IntAct

20 interactions, top by confidence:

A	B	Type	Score
TNIP1	NFKB1	psi-mi:“MI:0914”(association)	0.790
NUAK2	PPP1R12A	psi-mi:“MI:0914”(association)	0.640
GRIPAP1	NUAK2	psi-mi:“MI:0915”(physical association)	0.560
SFN	NUAK2	psi-mi:“MI:0915”(physical association)	0.560
NUAK2	SMAD3	psi-mi:“MI:0915”(physical association)	0.520
SMAD3	NUAK2	psi-mi:“MI:0915”(physical association)	0.520
YWHAE	NUAK2	psi-mi:“MI:0915”(physical association)	0.400
NUAK2	SMAD2	psi-mi:“MI:0915”(physical association)	0.400
TGFBR1	NUAK2	psi-mi:“MI:0915”(physical association)	0.400
NUAK2	HSP90AB1	psi-mi:“MI:0915”(physical association)	0.400
NUAK2	HSP90AA1	psi-mi:“MI:0914”(association)	0.350
NUAK2	PPP1R12A	psi-mi:“MI:0914”(association)	0.350
NUAK2	AP3D1	psi-mi:“MI:0914”(association)	0.350
NUAK2	GRIPAP1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (66): NUAK2 (Reconstituted Complex), HSP90AB3P (Affinity Capture-MS), LZTR1 (Affinity Capture-MS), PPP1R12A (Affinity Capture-MS), MARK3 (Affinity Capture-MS), UBXN7 (Affinity Capture-MS), FLNC (Affinity Capture-MS), BTRC (Affinity Capture-MS), AHCYL2 (Affinity Capture-MS), MARK2 (Affinity Capture-MS), FBXW11 (Affinity Capture-MS), DCAF5 (Affinity Capture-MS), USP7 (Affinity Capture-MS), NUAK2 (Affinity Capture-RNA), NUAK2 (Two-hybrid)

ESM2 similar proteins: A0AUV4, A1A5Q6, A1A5R7, A2KF29, B1WAS2, C0HKC8, C0HKC9, D3ZML2, O60285, O74536, O88831, O88866, P41279, P51956, P57058, P97756, Q20443, Q2T9U5, Q5R7G9, Q5XHI9, Q60670, Q63562, Q641K5, Q66HE5, Q68UT7, Q6P431, Q6VZ17, Q7T0B0, Q7T0B1, Q7TNJ7, Q7TNL4, Q8BHI9, Q8BZN4, Q8C078, Q8C0N0, Q8C0V7, Q8C0X8, Q8CIP4, Q8IY84, Q8K4K4

Diamond homologs: A1Z9X0, A2CI34, A2CI35, A8KBH6, A8XW88, F1M7Y5, O70146, P00542, P00543, P04409, P05126, P05128, P05129, P05696, P05771, P05772, P07332, P09215, P0CD62, P10102, P10829, P13678, P14238, P16054, P16879, P17252, P20444, P21137, P22612, P23298, P24723, P28867, P32866, P41743, P43057, P48562, P50527, P57078, P63318, P63319

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
STK11	up-regulates	NUAK2	phosphorylation
NUAK2	down-regulates	LATS1	phosphorylation
NUAK2	“up-regulates activity”	WDR45	phosphorylation
NUAK2	“down-regulates activity”	PPP1R12A	phosphorylation
NUAK2	“down-regulates activity”	LAT	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

115 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	95
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1184278	NM_030952.3(NUAK2):c.412_433delinsG (p.Tyr138_Gln145delinsGlu)	Pathogenic
3911831	NM_030952.3(NUAK2):c.1666C>T (p.Gln556Ter)	Likely pathogenic

SpliceAI

1143 predictions. Top by Δscore:

Variant	Effect	Δscore
1:205304509:GGCAT:G	acceptor_gain	1.0000
1:205304510:GCAT:G	acceptor_gain	1.0000
1:205304511:CAT:C	acceptor_gain	1.0000
1:205304511:CATC:C	acceptor_gain	1.0000
1:205304511:CATCT:C	acceptor_loss	1.0000
1:205304512:AT:A	acceptor_gain	1.0000
1:205304512:ATCTG:A	acceptor_loss	1.0000
1:205304513:TCT:T	acceptor_loss	1.0000
1:205304514:C:CA	acceptor_loss	1.0000
1:205304514:C:CC	acceptor_gain	1.0000
1:205304515:T:A	acceptor_loss	1.0000
1:205304522:C:CT	acceptor_gain	1.0000
1:205304523:A:T	acceptor_gain	1.0000
1:205305193:A:AC	donor_gain	1.0000
1:205305194:C:CC	donor_gain	1.0000
1:205305196:CA:C	donor_loss	1.0000
1:205305197:A:AC	donor_gain	1.0000
1:205305197:AC:A	donor_gain	1.0000
1:205305198:C:CT	donor_gain	1.0000
1:205305198:CC:C	donor_gain	1.0000
1:205305198:CCA:C	donor_gain	1.0000
1:205305198:CCAG:C	donor_gain	1.0000
1:205305198:CCAGA:C	donor_gain	1.0000
1:205305327:TCCAC:T	acceptor_gain	1.0000
1:205305328:CCACC:C	acceptor_gain	1.0000
1:205305329:CAC:C	acceptor_gain	1.0000
1:205305332:C:CC	acceptor_gain	1.0000
1:205305332:C:CG	acceptor_loss	1.0000
1:205306183:CTTA:C	donor_loss	1.0000
1:205306184:TTACC:T	donor_loss	1.0000

AlphaMissense

4085 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:205306299:G:C	D193E	1.000
1:205306299:G:T	D193E	1.000
1:205306300:T:A	D193V	1.000
1:205306300:T:G	D193A	1.000
1:205306301:C:G	D193H	1.000
1:205308211:T:A	D175V	1.000
1:205308211:T:G	D175A	1.000
1:205308214:C:G	R174P	1.000
1:205311814:C:A	K81N	1.000
1:205311814:C:G	K81N	1.000
1:205305272:A:C	F250L	0.999
1:205305272:A:T	F250L	0.999
1:205305274:A:G	F250L	0.999
1:205305276:G:T	P249H	0.999
1:205305322:A:G	W234R	0.999
1:205305322:A:T	W234R	0.999
1:205305328:C:G	D232H	0.999
1:205306242:G:C	S212R	0.999
1:205306242:G:T	S212R	0.999
1:205306244:T:G	S212R	0.999
1:205306246:C:T	G211E	0.999
1:205306291:A:G	L196P	0.999
1:205306300:T:C	D193G	0.999
1:205306303:G:T	A192D	0.999
1:205308195:G:C	N180K	0.999
1:205308195:G:T	N180K	0.999
1:205308210:A:C	D175E	0.999
1:205308210:A:T	D175E	0.999
1:205308211:T:C	D175G	0.999
1:205311758:T:A	E100V	0.999

dbSNP variants (sampled 300 via entrez): RS1000065722 (1:205314387 C>A,G), RS1000067557 (1:205315850 G>A,T), RS1000098269 (1:205316190 A>G), RS1000136971 (1:205315956 A>G), RS1000458589 (1:205303613 T>A,G), RS1000786912 (1:205304809 A>G), RS1000845560 (1:205321933 A>C), RS1001001055 (1:205301938 A>C), RS1001047192 (1:205302013 C>G), RS1001115106 (1:205308391 C>T), RS1001276124 (1:205322164 T>A,C), RS1001438335 (1:205310455 G>C,T), RS1001691733 (1:205313050 G>T), RS1001852357 (1:205306911 G>A), RS1002033654 (1:205311464 A>G)

Disease associations

OMIM: gene MIM:608131 | disease phenotypes: MIM:619452

GenCC curated gene-disease

Disease	Classification	Inheritance
anencephaly 2	Moderate	Autosomal recessive

Mondo (1): anencephaly 2 (MONDO:0030338)

Orphanet (0):

HPO phenotypes

9 total (9 of 9 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000161	Median cleft upper lip
HP:0000528	Anophthalmia
HP:0002323	Anencephaly
HP:0003577	Congenital onset
HP:0009099	Median cleft palate
HP:0010289	Cleft maxillary alveolar ridge
HP:0011803	Bifid nose
HP:0012745	Short palpebral fissure

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST005993_65	Mean corpuscular hemoglobin	1.000000e-10
GCST010002_349	Refractive error	8.000000e-13
GCST010143_9	Meat-related diet	4.000000e-11
GCST010697_12	Cortical surface area (min-P)	6.000000e-10
GCST010698_16	Subcortical volume (min-P)	8.000000e-09
GCST010699_52	Brain morphology (min-P)	5.000000e-08
GCST010700_66	Cortical thickness (MOSTest)	3.000000e-09
GCST010701_17	Cortical surface area (MOSTest)	5.000000e-08
GCST010702_2	Subcortical volume (MOSTest)	3.000000e-08
GCST010703_27	Brain morphology (MOSTest)	5.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5698 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

34 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 330,942 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1289926	AXITINIB	4	15,732
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL180022	NERATINIB	4	9,404
CHEMBL2103743	TOFACITINIB CITRATE	4	1,672
CHEMBL221959	TOFACITINIB	4	10,408
CHEMBL288441	BOSUTINIB	4	12,255
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL939	GEFITINIB	4	117,814
CHEMBL270995	BRIVANIB ALANINATE	3	1,077
CHEMBL300138	ENZASTAURIN	3	3,209
CHEMBL3137331	DEFACTINIB	3	1,229
CHEMBL3904602	LEROCICLIB	3	1,012
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL91829	RUBOXISTAURIN	3	77
CHEMBL1721885	SU-014813	2
CHEMBL3115681	NARAZACICLIB	2
CHEMBL402548	DANUSERTIB	2
CHEMBL475251	R-406	2
CHEMBL572878	TOZASERTIB	2
CHEMBL575448	BMS-754807	2
CHEMBL607707	PELITINIB	2
CHEMBL1908394	GSK-461364	1
CHEMBL1908397	KW-2449	1
CHEMBL296468	BMS-387032	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — NuaK subfamily

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
WZ4003	Inhibition	7.0	pIC50
HTH-02-006	Inhibition	6.9	pIC50

Binding affinities (BindingDB)

11 measured of 11 human assays (11 total across all organisms); most potent 11 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
PKC-412	KD	190 nM
(3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril	KD	520 nM
(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1^{7,14}.0^{2,6}.0^{8,13}.0^{22,27}]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione	KD	700 nM
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide	KD	1100 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM
(E)-N-[4-(3-chloro-4-fluoro-anilino)-3-cyano-7-ethoxy-6-quinolyl]-4-(dimethylamino)but-2-enamide	KD	3500 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile	KD	5000 nM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S)-3-hydroxy-1-methyl-4-piperidinyl]-1-benzopyran-4-one	KD	5300 nM

ChEMBL bioactivities

89 potent at pChembl≥5 of 90 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.07	Kd	0.086	nM	STAUROSPORINE
9.15	Kd	0.7	nM	LEROCICLIB
9.00	Kd	1	nM	LESTAURTINIB
8.92	Kd	1.2	nM	TAE-684
8.79	IC50	1.62	nM	STAUROSPORINE
8.78	IC50	1.67	nM	STAUROSPORINE
8.72	IC50	1.9	nM	STAUROSPORINE
8.52	Kd	3	nM	BRIVANIB ALANINATE
8.46	Kd	3.5	nM	CHEMBL4284499
8.30	IC50	5.012	nM	NARAZACICLIB
8.15	Kd	7	nM	CYC-116
8.00	Kd	10	nM	CHEMBL4465866
8.00	Kd	10	nM	CHEMBL1229592
7.96	Kd	11	nM	CHEMBL4576489
7.80	IC50	15.85	nM	CHEMBL6175168
7.68	Kd	21	nM	NINTEDANIB
7.64	Kd	23	nM	GSK-461364
7.62	Kd	24	nM	PF-03814735
7.60	Kd	25	nM	DANUSERTIB
7.60	IC50	25.12	nM	CHEMBL190684
7.60	IC50	25.12	nM	CHEMBL6177408
7.58	Kd	26	nM	JNJ-7706621
7.40	IC50	39.81	nM	CHEMBL6167301
7.31	Kd	49	nM	FEDRATINIB
7.27	Kd	54	nM	KW-2449
7.20	Kd	63	nM	MIDOSTAURIN
7.20	IC50	63.1	nM	CHEMBL6177133
7.19	Kd	65	nM	R-406
7.14	Kd	72	nM	LESTAURTINIB
7.07	Kd	86	nM	GSK-690693
7.00	IC50	100	nM	CHEMBL4303523
7.00	IC50	100	nM	CHEMBL6163620
6.92	IC50	120	nM	CHEMBL5199998
6.92	Kd	120	nM	CRIZOTINIB
6.90	IC50	126	nM	CHEMBL5202966
6.90	IC50	125.9	nM	CHEMBL6170125
6.89	Kd	130	nM	DOVITINIB
6.89	Kd	130	nM	CHEMBL1908395
6.85	Kd	140	nM	NERATINIB
6.82	Kd	150	nM	SUNITINIB
6.66	Kd	220	nM	BOSUTINIB
6.62	Kd	240	nM	TOFACITINIB CITRATE
6.62	Kd	240	nM	TOFACITINIB
6.50	Kd	320	nM	RUBOXISTAURIN
6.50	Kd	320	nM	RUXOLITINIB
6.40	Kd	400	nM	SU-014813
6.38	Kd	420	nM	TOFACITINIB CITRATE
6.38	Kd	420	nM	TOFACITINIB
6.36	Kd	440	nM	CGP-52421
6.34	Kd	454	nM	DEFACTINIB

PubChem BioAssay actives

74 with measured affinity, of 551 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	435559: Binding constant for SNARK kinase domain	kd	0.0001	uM
4-[[5-(4-propan-2-ylpiperazin-1-yl)-2-pyridinyl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1’-cyclohexane]-10-one	1609450: Binding affinity to SNARK (unknown origin)	kd	0.0007	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	508088: Binding affinity to SNARK	kd	0.0010	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	1845591: Binding affinity to NUAK2 (unknown origin) assessed as dissociation constant	kd	0.0012	uM
[(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate	1425095: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0030	uM
9-(cyclohexylmethyl)-4,5-dimethoxy-9,14,16-triazatetracyclo[8.7.0.02,7.011,15]heptadeca-1(17),2,4,6,10,12,15-heptaen-8-one	1415053: Binding affinity to DNA-tagged recombinant human SNARK (22 to 333 residues) expressed in mammalian expression system by KINOMEscan assay	kd	0.0035	uM
4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine	1425095: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0070	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526222: Binding affinity to recombinant full-length N-terminal His-FLAG-tagged NUAK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.0100	uM
N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide	2185074: Binding affinity to SNARK (unknown origin) assessed as dissociation constant	kd	0.0100	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylamino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526222: Binding affinity to recombinant full-length N-terminal His-FLAG-tagged NUAK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.0110	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	625139: Binding constant for SNARK kinase domain	kd	0.0210	uM
5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide	1845591: Binding affinity to NUAK2 (unknown origin) assessed as dissociation constant	kd	0.0230	uM
N-[2-[4-[[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-11-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-11-yl]-2-oxoethyl]acetamide	1425095: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0240	uM
N-[5-[(2R)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1H-pyrrolo[3,4-d]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide	1425095: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0250	uM
4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	435559: Binding constant for SNARK kinase domain	kd	0.0260	uM
Fedratinib	625139: Binding constant for SNARK kinase domain	kd	0.0490	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	625139: Binding constant for SNARK kinase domain	kd	0.0540	uM
Midostaurin	435559: Binding constant for SNARK kinase domain	kd	0.0630	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	625139: Binding constant for SNARK kinase domain	kd	0.0650	uM
4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-piperidin-3-yl]methoxy]imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol	625139: Binding constant for SNARK kinase domain	kd	0.0860	uM
N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]propanamide	1845578: Inhibition of N-terminal GST-tagged human NUAK2 expressed in Escherichia coli DH5alpha incubated for 30 mins in presence of gamma-[32P]ATP by cerenkov counting analysis	ic50	0.1000	uM
Crizotinib	625139: Binding constant for SNARK kinase domain	kd	0.1200	uM
7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-2-methylsulfonylpyrrolo[2,3-d]pyrimidin-6-one	1845564: Inhibition of NUAK2 (unknown origin)	ic50	0.1200	uM
N-[3-[5-iodo-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]butanamide	1845564: Inhibition of NUAK2 (unknown origin)	ic50	0.1260	uM
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	435559: Binding constant for SNARK kinase domain	kd	0.1300	uM
5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide;hydrochloride	625139: Binding constant for SNARK kinase domain	kd	0.1300	uM
Neratinib	625139: Binding constant for SNARK kinase domain	kd	0.1400	uM
Sunitinib	435559: Binding constant for SNARK kinase domain	kd	0.1500	uM
Bosutinib	625139: Binding constant for SNARK kinase domain	kd	0.2200	uM
Tofacitinib	625139: Binding constant for SNARK kinase domain	kd	0.2400	uM
(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione	435559: Binding constant for SNARK kinase domain	kd	0.3200	uM
Ruxolitinib	625139: Binding constant for SNARK kinase domain	kd	0.3200	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	435559: Binding constant for SNARK kinase domain	kd	0.4000	uM
N-[(2S,3R,4R,6R,18S)-18-hydroxy-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide	508088: Binding affinity to SNARK	kd	0.4400	uM
N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide	1425095: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.4540	uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide	435559: Binding constant for SNARK kinase domain	kd	0.5300	uM
5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide	1425095: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.7050	uM
N-[3-[[5-bromo-4-[(4-sulfamoylphenyl)methylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide	1823799: Inhibition of full length recombinant human NUAK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate incubated for 40 mins in presence of [gamma-33P-ATP] by radiometric scintillation assay	ic50	0.9000	uM
(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one	625139: Binding constant for SNARK kinase domain	kd	0.9100	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148895: Binding affinity to human NUAK2 incubated for 45 mins by Kinobead based pull down assay	kd	1.0108	uM
4-[[[5-bromo-2-[[3-methyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]methyl]benzenesulfonamide	1823799: Inhibition of full length recombinant human NUAK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate incubated for 40 mins in presence of [gamma-33P-ATP] by radiometric scintillation assay	ic50	1.1510	uM
Axitinib	625139: Binding constant for SNARK kinase domain	kd	1.3000	uM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one	435559: Binding constant for SNARK kinase domain	kd	1.4000	uM
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide	435559: Binding constant for SNARK kinase domain	kd	1.7000	uM
(2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methylpyrrolidine-2-carboxamide	2167411: Binding affinity to NUAK2 (unknown origin) by phage based competition assay	kd	1.8000	uM
N-[3-[[5-cyclopropyl-2-[3-(morpholin-4-ylmethyl)anilino]pyrimidin-4-yl]amino]propyl]cyclobutanecarboxamide	1845564: Inhibition of NUAK2 (unknown origin)	ic50	2.6000	uM
(4-hydroxypiperidin-1-yl)-[4-[[4-[4-(3-methylsulfonylpropoxy)indol-1-yl]pyrimidin-2-yl]amino]cyclohexyl]methanone	769495: Binding affinity to SNARK (unknown origin)	kd	2.6000	uM
(E)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide	435559: Binding constant for SNARK kinase domain	kd	2.7000	uM
2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	625139: Binding constant for SNARK kinase domain	kd	3.6000	uM
3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione	625139: Binding constant for SNARK kinase domain	kd	4.1000	uM

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	3
perfluorooctane sulfonic acid	decreases expression, increases expression	2
Arsenic	affects expression, affects methylation	2
Methotrexate	affects cotreatment, increases expression, decreases expression	2
Silicon Dioxide	decreases methylation, increases expression	2
Silver	increases expression	2
Cyclosporine	decreases expression, increases expression	2
Aflatoxin B1	decreases methylation, increases expression	2
aristolochic acid I	increases expression	1
Glupearl 19S	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
titanium dioxide	decreases methylation	1
salinomycin	decreases expression	1
quercitrin	decreases expression	1
trichostatin A	decreases expression	1
sodium arsenite	increases expression	1
zinc chromate	decreases expression, increases abundance	1
potassium chromate(VI)	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
polyhexamethyleneguanidine	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
CGP 52608	increases reaction, affects binding	1
2-palmitoylglycerol	increases expression	1
abrine	increases expression	1
jinfukang	decreases expression, increases reaction	1
WZ4003	decreases activity	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1

ChEMBL screening assays

200 unique, capped per target: 200 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1017050	Binding	Binding affinity to SNARK	Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.